Abstract
Point-of-care detection of pathogens is critical to monitor and combat viral infections. Here, we demonstrate a plasmonic coupling assay (PCA) using gold nanourchins (AuNUs) as labels for the colorimetric quantification of viruses. The antibody functionalized AuNUs allow for rapid and highly specific identification of viruses and provide strong color change for sensitive detection. Using respiratory syncytial virus (RSV) as a target, we demonstrate that the AuNU-based PCA achieves a detection limit of 1,402 PFU/mL (equivalent to 17 copies/μL) that is 3.1- and 5.7-times lower than the rod- and sphere-based counterparts, respectively. The improved detection sensitivity arises from the higher virus binding capability and stronger plasmonic coupling at long distances (∼10 nm) by AuNU probes. The detection can be performed with a portable smartphone-based spectrometer and is validated by testing RSV-spiked nasal swab clinical samples. Our study reports a rapid and sensitive approach for intact virus detection and provides a potential toolkit at the point of care.
Competing Interest Statement
Y.L. Z.Q. H.Y. and J.S.K. are the inventors on a provisional patent related to this work filed by the University of Texas at Dallas. Z.Q. and J.S.K. hold equity interest in Avsana Labs, Incorporated, which aims to commercialize the technology. The remaining authors declare no competing financial interest.
Funding Statement
Research reported in this manuscript was partially supported by National Institutes of Health (NIH) grants R21AI140462 and R01AI151374 and U.S. Department of Defense (DOD) grant PR192581 to Z.Q.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Texas at Dallas Institutional Biosafety & Chemical Safety Committee and the Institutional Review Board gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
